Article
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Clinical immunology (Orlando, Fla.) - 1 Jun 2018
Weinhold Kent J, Bukowski Jack F, Brennan Todd V, Noveck Robert J, Staats Janet S, Lin Liwen, Stempora Linda, Hammond Constance, Wouters Ann, Mojcik Christopher F, Cheng John, Collinge Mark, Jesson Michael I, Hazra Anasuya, Biswas Pinaki, Lan Shuping, Clark James D, Hodge Jennifer A
Abstract excerpt
This study evaluated the short-term effects of tofacitinib treatment on peripheral blood leukocyte phenotype and function, and the reversibility of any such effects following treatment withdrawal in healthy volunteers. Cytomegalovirus (CMV)-seropositive subjects received oral tofacitinib 10 mg twice daily for 4 weeks and were followed for 4 weeks after drug withdrawal. There were slight increases in total...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
